Response data. (A) Summary of overall response data for all patients and by refractory status (double refractory to IMiDs and proteosome inhibitors) and by high-risk cytogenetics. (B) Relative change in paraprotein level from baseline for all evaluable patients (n = 45). (C) Duration of remission for patients achieving objective responses.